Wijnand Helfrich
0000-0001-7004-3995
100 papers found
Refreshing results…
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells
Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles
Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
Modular medical imaging agents based on azide‐alkyne Huisgen cycloadditions: Synthesis and pre‐clinical evaluation of 18F‐labeled PSMA‐tracers for prostate cancer imaging.
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
Melanoma-directed activation of apoptosis using a bispecific antibody directed at MCSP and TRAIL receptor 2/Death Receptor 5
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux
GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity
The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity
CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab′)2 and Fab fragments in nude mice with PSMA-expressing xenografts
Missing publications? Search for publications with a matching author name.